Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations

被引：39

作者：

Berrocal, Alfonso ^{[1
]}

Cabanas, Luis ^{[2
]}

Espinosa, Enrique ^{[3
]}

Fernandez-de-Misa, Ricardo ^{[4
]}

Martin-Algarra, Salvador ^{[5
]}

Carlos Martinez-Cedres, Jose ^{[6
]}

Rios-Buceta, Luis ^{[7
]}

Luis Rodriguez-Peralto, Jose ^{[8
]}

机构：

[1] Hosp Gen Univ, Dept Oncol, Valencia, Spain

[2] Hosp Ramon & Cajal, Dept Surg, E-28034 Madrid, Spain

[3] Hosp Univ La Paz, Dept Clin Oncol, Madrid, Spain

[4] Hosp Nuestra Senora Candelaria, Dept Dermatol, San Cristobal la Laguna, Spain

[5] Univ Navarra Clin, Dept Oncol, Pamplona, Spain

[6] Hosp Nuestra Senora Candelaria, Dept Radiotherapeut Oncol, San Cristobal la Laguna, Spain

[7] Hosp Ramon & Cajal, Dept Dermatol, E-28034 Madrid, Spain

[8] Hosp Univ 12 Octubre, Dept Pathol, Madrid, Spain

来源：

ADVANCES IN THERAPY | 2014年 / 31卷 / 09期

关键词：

Diagnosis; Malignant melanoma; Oncology; Prognosis; Spain; Standards; Therapeutics; HIGH-RISK MELANOMA; CUTANEOUS MALIGNANT-MELANOMA; PIGMENTED SKIN-LESIONS; RANDOMIZED PHASE-III; ONCOLOGY-GROUP TRIAL; LOW-DOSE INTERFERON-ALPHA-2B; ADJUVANT THERAPY; IMPROVED SURVIVAL; METASTATIC MELANOMA; MELANOCYTIC NEVI;

D O I：

10.1007/s12325-014-0148-2

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

100103 [病原生物学]; 100218 [急诊医学];

摘要：

The incidence of malignant melanoma is increasing worldwide. In Spain, its incidence is increasing faster than any other cancer type, with a 5-year survival rate of about 85%. The impact and characteristics of malignant melanoma in the Spanish population can be ascertained from the national melanoma registry of the Academia Espaola de Dermatologia y Venereologia. This review presents consensus group recommendations for the diagnosis, staging and treatment of malignant melanoma in Spain. Incidence and mortality are discussed, as well as evaluation of various prevention and treatment strategies. Prognostic factors, such as BRAF and C-KIT mutations, which are expected to become routine staging procedures over the next few years, are outlined, especially in relation to treatment options. The use of recently approved targeted agents such as ipilimumab, a cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitor, and vemurafenib, a BRAF inhibitor, in metastatic disease are also discussed.

引用

页码：945 / 960

页数：16

共 115 条

[1]

Early diagnosis of cutaneous melanoma - Revisiting the ABCD criteria [J].

Abbasi, NR ;

Shaw, HM ;

Rigel, DS ;

Friedman, RJ ;

McCarthy, WH ;

Osman, I ;

Kopf, AW ;

Polsky, D .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (22) :2771-2776

[2]

Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697) [J].

Agarwala, S. S. ;

Lee, S. J. ;

Flaherty, L. E. ;

Smylie, M. ;

Kefford, R. F. ;

Carson, W. E. ;

Cohen, G. ;

Kirkwood, J. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[3]

Analysis of Factors Influencing Outcome in Patients With In-Transit Malignant Melanoma Undergoing Isolated Limb Perfusion Using Modern Treatment Parameters [J].

Alexander, H. Richard, Jr. ;

Fraker, Douglas L. ;

Bartlett, David L. ;

Libutti, Steven K. ;

Steinberg, Seth M. ;

Soriano, Perry ;

Beresnev, Tatiana .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :114-118

[4]

Progression in cutaneous malignant melanoma is associated with distinct expression profiles -: A tissue microarray-based study [J].

Alonso, SR ;

Ortiz, P ;

Pollán, M ;

Pérez-Gómez, B ;

Sánchez, L ;

Acuña, MJ ;

Pajares, R ;

Martínez-Tello, FJ ;

Hortelano, CM ;

Piris, MA ;

Rodríguez-Peralto, JL .

AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (01) :193-203

[5]

MELANOMA - IT CANT BE MELANOMA - A SUBSET OF MELANOMAS THAT DEFIES CLINICAL RECOGNITION [J].

ANDERSEN, WK ;

SILVERS, DN .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (24) :3463-3465

[6]

Sensitivity, specificity, and diagnostic accuracy of three dermoscopic algorithmic methods in the diagnosis of doubtful melanocytic lesions [J].

Annessi, Giorgio ;

Bono, Riccardo ;

Sampogna, Francesca ;

Faraggiana, Tullio ;

Abeni, Damiano .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (05) :759-767

[7]

Dermoscopy of pigmented skin lesions:: Results of a consensus meeting via the Internet [J].

Argenziano, G ;

Soyer, HP ;

Chimenti, S ;

Talamini, R ;

Corona, R ;

Sera, F ;

Binder, M ;

Cerroni, L ;

De Rosa, G ;

Ferrara, G ;

Hofmann-Wellenhof, R ;

Landthater, M ;

Menzies, SW ;

Pehamberger, H ;

Piccolo, D ;

Rabinovitz, HS ;

Schiffner, R ;

Staibano, S ;

Stolz, W ;

Bartenjev, I ;

Blum, A ;

Braun, R ;

Cabo, H ;

Carli, P ;

De Giorgi, V ;

Fleming, MG ;

Grichnik, JM ;

Grin, CM ;

Halpern, AC ;

Johr, R ;

Katz, B ;

Kenet, RO ;

Kittler, H ;

Kreusch, J ;

Malvehy, J ;

Mazzocchetti, G ;

Oliviero, M ;

Özdemir, F ;

Peris, K ;

Perotti, R ;

Perusquia, A ;

Pizzichetta, MA ;

Puig, S ;

Rao, B ;

Rubegni, P ;

Saida, T ;

Scalvenzi, M ;

Seidenari, S ;

Stanganelli, I ;

Tanaka, M .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 48 (05) :679-693

[8]

PLANTAR LENTIGINOUS MELANOMA - DISTINCTIVE VARIANT OF HUMAN CUTANEOUS MALIGNANT-MELANOMA [J].

ARRINGTON, JH ;

REED, RJ ;

ICHINOSE, H ;

KREMENTZ, ET .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1977, 1 (02) :131-143

[9]

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma:: A phase III study [J].

Avril, MF ;

Aamdal, S ;

Grob, JJ ;

Hauschild, A ;

Mohr, P ;

Bonerandi, JJ ;

Weichenthal, M ;

Neuber, K ;

Bieber, T ;

Gilde, K ;

Porta, VG ;

Fra, J ;

Bonneterre, J ;

Saïag, P ;

Kamanabrou, D ;

Pehamberger, H ;

Sufliarsky, J ;

Larriba, JLG ;

Scherrer, A ;

Menu, Y .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1118-1125

[10]

Predicting outcomes in metastatic Melanoma [J].

Balch, Charles M. ;

Soong, Seng-jaw .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) :168-169

← 1 2 3 4 5 6 7 8 9 10 →